ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1732

Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA)

Huiyi Wang1, Kangkang Luo1, Shuxin Xu1, Jiayin Zhou1, Santi Chen2, Jun wang2, Wenzhao Li2, Jing Zhao1 and Cunxiang Ju1, 1GemPharmatech CO., Ltd., Nanjing, China, 2GemPharmatech LLC, La Jolla, CA

Meeting: ACR Convergence 2023

Keywords: immunology, Inflammation, Joint Structure, rheumatoid arthritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1713–1733) RA – Animal Models Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The differences between human and mouse immune systems make it challenging to accurately reflect the immunopathogenesis of autoimmune diseases in patients. Therefore, translational research needs to shift focus from mouse immunology to human immunology. In addressing these challenges, the HSC-NCG-M mice have emerged as a valuable model. Gempharmatech developed the HSC-NCG-M mouse model to support the development of human T, B, NK, and myeloid cells more effectively. The HSC-NCG-M mouse model is genetically engineered on the severe immunodeficient NCG strain and produces human granulocyte/macrophage colony-stimulating factor 2 (GM-CSF, also known as CSF2), interleukin-3 (IL-3), and stem cell factor (SCF, also known as KITLG).

Methods: This study describes the construction process of the RA model in HSC-NCG-M mice. Female NCG-M mice (4-6 weeks old) were engrafted with CD34+ HSC after irradiation. The RA model was induced by injecting Complete Freund’s Adjuvant (CFA) into the foot pads of the hind limbs. The body weight, graft-versus-host disease (GvHD) score and the development of arthritis in the hind limbs of the mice were monitored three times a week. The arthritis score for each mouse was obtained by summing the scores for both hind limbs. The volume of the left and right hind limbs, including the joint of the paw and ankle, was measured three times a week using a claw measuring instrument until the end of the experiment.

Results: In the CFA-induced RA model based on HSC-NCG-M mice, there was an increasing number of human CD4+ T lymphocytes, Th17, Treg, and monocytes in peripheral blood, along with elevated IL-6 levels, which closely resembled clinical phenotypes of RA patients. Compared to the control group, HSC-NCG-M mice injected with CFA in the foot pads showed increased arthritis scores and swelling thickness in the hind limbs.

Conclusion: This model develop a fully functional human immune system capable of innate and adaptive immune responses. The CFA-induced RA model primarily involves the human immune system and closely resembles human RA patients. Therefore, the HSC-NCG-M mouse model is an appropriate model for studying RA, as it involves the engagement of the human immune system.


Disclosures: H. Wang: None; K. Luo: None; S. Xu: None; J. Zhou: None; S. Chen: None; J. wang: None; W. Li: None; J. Zhao: None; C. Ju: None.

To cite this abstract in AMA style:

Wang H, Luo K, Xu S, Zhou J, Chen S, wang J, Li W, Zhao J, Ju C. Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/immunopathogenesis-and-preclinical-trials-in-a-humanized-mouse-model-of-rheumatoid-arthritisra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunopathogenesis-and-preclinical-trials-in-a-humanized-mouse-model-of-rheumatoid-arthritisra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology